Advertisement

Botulinum Toxin

  • Kris Ferguson
  • Nicole Wolfgram
Chapter

Abstract

Botulinum toxin is a neurotoxin protein produced by the bacterium Clostridium botulinum and related species. There are seven types of botulinum toxin, types A–G, but only types A and B are FDA approved to be used in humans. There are multiple uses for Botox in the management of pain, but the only FDA-approved indications are cervical dystonia, chronic migraine, and limb spasticity. Further research is needed to establish efficacy in other pain conditions such as neuralgias and myofascial pain syndromes. Dosing is variable based on the type used and the area being injected. The duration of action of botulinum toxin is dependent on the type of botulinum used A vs. B, dose, method of administration, and the type of synapse affected (muscle vs. cholinergic synapse).

Keywords

Botox Botulinum toxin Onabotulinum toxin A Rimabotulinum toxin B Headache Migraine Dystonia Neuropathy Neuralgia Myofascial pain 

Recommended Reading

  1. 1.
    Beal B, Wallace M. An overview of pharmacologic management of chronic pain. Med Clin N Am. 2016;100(1):65–79.CrossRefGoogle Scholar
  2. 2.
    Bomba-Warczak E, Vevea J, Brittain J, Figueroa-Bernier A, Tepp W, Johnson E, et al. Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons. Cell Rep. 2016;16(7):1974–87.CrossRefGoogle Scholar
  3. 3.
    Broide R, Cai B, Francis J, Brin M. Botulinum neurotoxin type A–cleaved SNAP25 is confined to primary motor neurons and expressed on the plasma membrane following intramuscular toxin injection. Toxicon. 2016;123:S8.CrossRefGoogle Scholar
  4. 4.
    Godoy I, Donahue D, Torriani M. Botulinum toxin injections in musculoskeletal disorders. Semin Musculoskelet Radiol. 2016;20(05):441–52.CrossRefGoogle Scholar
  5. 5.
    Halder G, Scott L, Wyman A, Mora N, Miladinovic B, Bassaly R, et al. Botox combined with myofascial release physical therapy as a treatment for myofascial pelvic pain. Investig Clin Urol. 2017;58(2):134.CrossRefGoogle Scholar
  6. 6.
    Hong B, Yao L, Ni L, Wang L, Hu X. Antinociceptive effect of botulinum toxin A involves alterations in AMPA receptor expression and glutamate release in spinal dorsal horn neurons. Neuroscience. 2017;357:197–207.CrossRefGoogle Scholar
  7. 7.
    Kermen R. Botulinum toxin for chronic pain conditions. Dis Mon. 2016;62(9):353–7.CrossRefGoogle Scholar
  8. 8.
    Matak I, Riederer P, Lackovic Z. Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem Int. 2012;61(2):236–9.CrossRefGoogle Scholar
  9. 9.
    Mittal S, Safarpour D, Jabbari B. Botulinum toxin treatment of neuropathic pain. Semin Neurol. 2016;36(01):073–83.CrossRefGoogle Scholar
  10. 10.
    Moon Y, Choi J, Park H, Park J, Kim J. Ultrasound-guided nerve block with botulinum toxin type a for intractable neuropathic pain. Toxins. 2016;8(1):18.CrossRefGoogle Scholar
  11. 11.
    Morra M, Elgebaly A, Elmaraezy A, Khalil A, Altibi A, Vu T, et al. Therapeutic efficacy and safety of botulinum toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain. 2016;17(1):63.CrossRefGoogle Scholar
  12. 12.
    Oh H, Chung M. Botulinum toxin for neuropathic pain: a review of the literature. Toxins. 2015;7(8):3127–54.CrossRefGoogle Scholar
  13. 13.
    Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35.CrossRefGoogle Scholar
  14. 14.
    Silberstein S. The use of botulinum toxin in the management of headache disorders. Semin Neurol. 2016;36(01):092–8.CrossRefGoogle Scholar
  15. 15.
    Singer B, Silbert B, Silbert P, Singer K. The role of botulinum toxin type A in the clinical management of refractory anterior knee pain. Toxins. 2015;7(9):3388–404.CrossRefGoogle Scholar
  16. 16.
    Wheeler A, Smith H. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–46.CrossRefGoogle Scholar
  17. 17.
    Wissel J, Bensmail D, Ferreira J, Molteni F, Satkunam L, Moraleda S, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. Neurology. 2017;88(14):1321–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Kris Ferguson
    • 1
  • Nicole Wolfgram
    • 1
  1. 1.Aspirus HospitalWausauUSA

Personalised recommendations